CC 31244

Drug Profile

CC 31244

Alternative Names: CC-31244; CDI 31244

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cocrystal Discovery
  • Developer Cocrystal Pharma Inc
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 28 Jun 2018 Phase-II clinical trials in Hepatitis C in USA (PO) (NCT03501550)
  • 11 May 2018 Updated efficacy data from a phase Ia/Ib trial in Hepatitis C released by Cocrystal Pharma
  • 03 Apr 2018 Cocrystal Pharma plans a phase IIa trial for Hepatitis C in USA in second quarter of 2018 (NCT03501550)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top